How many years do patients with pulmonary fibrosis need to take pirfenidone/Axri?

Pulmonary fibrosis is a serious lung disease characterized by the gradual scarring of lung tissue, leading to difficulty breathing and decreased lung function. Pirfenidone/Aisri (Pirfenidone) is an anti-fibrotic drug widely used in pulmonary fibrosis-related diseases such as idiopathic pulmonary fibrosis (IPF). There's really no one-size-fits-all answer to when to use pirfenidone because each patient's condition, response, and tolerability may vary.

In general, pirfenidone treatment is usually long-term, and in many cases requires continued use for several years. Based on clinical studies, patients may need an evaluation period of at least 6 months after treatment to observe the drug's impact on disease progression. If the patient's condition is stable during this time and there are no significant side effects, the doctor may recommend continued treatment. Multiple studies have shown that long-term use of pirfenidone can effectively slow the progression of idiopathic pulmonary fibrosis, thereby improving patients' quality of life.

In clinical practice, many doctors will recommend that patients with pulmonary fibrosis undergo regular pulmonary function tests and imaging examinations after starting treatment to monitor disease progression and response to pirfenidone. If a patient experiences adverse reactions while taking the drug, the dose may need to be adjusted or the treatment regimen changed. Past data show that some patients can remain relatively stable on pirfenidone for many years, but this also depends on individual differences.

In addition, the treatment of pulmonary fibrosis does not only rely on pirfenidone, but may also involve other drugs and comprehensive treatment measures, such as oxygen therapy, rehabilitation training, etc. These treatments can help improve a patient's overall health and quality of life. Therefore, when considering the use of pirfenidone, patients should also communicate closely with their doctors to develop a personalized treatment plan.